Trials / Completed
CompletedNCT01336010
Treatment of Recently Acquired Hepatitis C Virus Infection
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Kirby Institute · Other Government
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether response guided treatment with pegylated interferon +/- ribavirin is effective for the treatment of recently acquired hepatitis C infection. Response guided treatment is when the length of treatment is determined by how quickly you respond to the treatment.
Detailed description
A prospective longitudinal study of natural history and treatment outcomes following response guided treatment of recent hepatitis C infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly |
| DRUG | Ribavirin | Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2011-04-15
- Last updated
- 2015-09-02
Locations
8 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT01336010. Inclusion in this directory is not an endorsement.